SolaranRx announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to SRX-1177 for the treatment of stage IIB to IV malignant melanoma.
Patients are injected with SRX-1177 to determine suitability for treatment through a standard imaging scan. Therapeutic doses of SRX-1177 are then injected to deliver targeted radiation to kill cancer cells, with minimal impact on healthy cells.
SolaranRx’s technology precisely targets deadly melanoma tumors with a novel radiolabeled peptide that selectively attaches to melanocortin-1 (MC1) receptors over-expressed on about 80% of melanoma samples.
For more information visit SolaranRx.com.